‘Glaring Gap’ Seen in DNA Privacy Pledges by 23andMe, Ancestry
By Kristen V Brown,
Bloomberg
| 08. 02. 2018
Genetic-testing companies that have decoded the DNA of millions just introduced new guidelines to protect data privacy.
But those best practices failed to address a major concern: what happens to customers’ data that is shared for research with pharmaceutical giants, academics and others, often for a profit.
Just how lucrative the business of genetic testing is came into light last week when British drugmaker GlaxoSmithKline Plc agreed to buy a $300 million stake in 23andMe Inc., gaining access to anonymized data with the hope of identifying new targets for drugs. That kind of data -- stripped of identifying details and aggregated -- isn’t strictly subject to new rules in the guidelines unveiled this week. That means consumers will still have little way to know when and how their information is combed for research.
“This new policy is a positive step forward in the sense that it’s starting a conversation,” said James Hazel, a researcher at Vanderbilt University in Nashville, Tennessee, who recently surveyed the privacy policies of 90 direct-to-consumer genetic-testing companies. “The glaring gap is that it doesn’t apply...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...